NEWARK, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today reported its financial results for the first quarter fiscal year 2026 ended October 31, 2025.

"We remain pleased with the progress of our pivotal Phase 3 TransportNPC™ study evaluating Trappsol^® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, which the Data Monitoring Committee (DMC) recommended continuing after their review of prespecified safety and efficacy data at 48 weeks. We believe that Trappsol^® Cyclo™ could provide an important new treatment option for patients suffering from this rare and fatal genetic disease," said Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings.

Rafael Holdings, Inc. First Quarter Fiscal Year 2026 Financial Results

As of October 31, 2025, we had cash and cash equivalents of $45.5 million.

For the three months ended October 31, 2025, we recorded a net loss attributable to Rafael Holdings of $9.8 million, or $0.19 per share, versus a net loss of $9.0 million, or $0.37 per share in the year ago period. The year over year increase in net loss is attributable to the consolidation of Cyclo Therapeutic's expenses following the acquisition of Cyclo in March 2025.

Research and development expenses were $7.5 million for the three months ended October 31, 2025, compared to $1.3 million in the year ago period. The year over year increase relates to the inclusion in the current year period of spending at Cyclo following the March 2025 acquisition.

General and administrative expenses were $2.8 million for the three months ended October 31, 2025, compared to $2.5 million in the year ago period. The year over year increase relates to the inclusion of expenses at Cyclo following the March 2025 acquisition.

About Rafael Holdings, Inc.

Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early stage companies that develop pharmaceuticals and medical devices. Our lead candidate is Trappsol® Cyclo™, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 ("NPC1"), a rare, fatal and progressive genetic disorder. We also hold interests in other clinical-stage and early-stage pharmaceutical development companies and an orthopedic-focused medical device company. Our lead candidate, Trappsol® Cyclo™, is the subject of an ongoing pivotal Phase 3 clinical trial.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; plans regarding the further evaluation of clinical data; and the potential of our pipeline, including our internal cancer metabolism research programs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, those disclosed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended July 31, 2024, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Contact:

Barbara Ryan

Barbara.ryan@rafaelholdings.com

(203) 274-2825

RAFAEL HOLDINGS, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)

	October 31, 2025			July 31, 2025
	(unaudited)
ASSETS

CURRENT ASSETS
Cash and cash equivalents	$	45,539		$	52,769
Prepaid clinical costs		1,584			1,045
Other receivables		—			1,206
Accounts receivable, net of allowance for credit losses of $245 at October 31, 2025 and July 31, 2025		413			627
Inventory		272			281
Prepaid expenses and other current assets		513			786
Total current assets		48,321			56,714

Property and equipment, net		1,562			1,596
Non-current prepaid clinical costs		629			1,399
Convertible notes receivable classified as available-for-sale		1,858			1,858
Goodwill		19,939			19,939
Intangible assets, net		962			994
In-process research and development		31,575			31,575
Investments		500			—
Other assets		29			34
TOTAL ASSETS	$	105,375		$	114,109

LIABILITIES AND EQUITY
CURRENT LIABILITIES
Accounts payable	$	6,794		$	6,893
Accrued expenses		3,860			3,304
Convertible notes payable		608			614
Due to related parties		751			723
Other current liabilities		63			66
Total current liabilities		12,076			11,600

Accrued expenses, noncurrent
Convertible notes payable, noncurrent		3,898			3,895
Deferred income tax liability		56			78
Other liabilities		138			138
TOTAL LIABILITIES		27			27
		16,195			15,738
COMMITMENTS AND CONTINGENCIES

EQUITY
Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of October 31, 2025 and July 31, 2025		8			8
Class B common stock, $0.01 par value; 200,000,000 shares authorized, 50,867,964 issued and outstanding (excluding treasury shares of 101,487) as of October 31, 2025, and 50,789,697 issued and outstanding (excluding treasury shares of 101,487) as of July 31, 2025		509			508
Additional paid-in capital		322,730			322,161
Accumulated deficit		(242,079	)		(232,263	)
Treasury stock, at cost; 101,487 Class B shares as of October 31, 2025 and July 31, 2025		(168	)		(168	)
Accumulated other comprehensive income related to unrealized income on available-for-sale securities		358			358
Accumulated other comprehensive income related to foreign currency translation adjustment		3,823			3,787
Total equity attributable to Rafael Holdings, Inc.		85,181			94,391
Noncontrolling interests		3,999			3,980
TOTAL EQUITY		89,180			98,371

TOTAL LIABILITIES AND EQUITY	$	105,375		$	114,109

RAFAEL HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(unaudited, in thousands, except share and per share data)


	Three Months Ended October 31,
		2025			2024
Revenues	$	240		$	128

Cost of infusion Technology revenue		-			37
Cost of product revenue		9			-
SG&A Expenses		2,838			2,523
R&D Expenses		7,484			1,326
Depreciation and amortization		50			86
Operating Loss		(10,141	)		(3,844	)

Interest income		399			568
Realized gain on available-for-sale securities		-			194
Unrealized loss on investments - Cyclo Therapeutics Inc.		-			(4,365	)
Unrealized loss on convertible notes receivable, due from Cyclo		-			(1,588	)
Interest expense		(160	)		(162	)
Other income (loss)		115			(2	)
Loss before Incomes Taxes		(9,787	)		(9,199	)
Taxes		(10	)		(12	)

Consolidated net loss		(9,797	)		(9,211	)
Net income (loss) attributable to noncontrolling interests		19			(205	)
Net loss attributable to Rafael Holdings, Inc.	$	(9,816	)	$	(9,006	)

Continuing operations loss per share
Net loss from operations		(9,797	)		(9,211	)
Net income (loss) attributable to noncontrolling interests		19			(205	)
Numerator for loss per share from operations	$	(9,816	)	$	(9,006	)


Loss per share
Basic and diluted		(0.19	)		(0.37	)
Loss per basic common share	$	(0.19	)	$	(0.37	)

Weighted average shares in calculation		51,184,407			24,062,854

Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results